checkAd

Xencor to Present at Upcoming Investor Conferences

Nachrichtenquelle: Business Wire (engl.)
04.02.2021, 22:01  |  63   |   |   

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

  • Guggenheim Healthcare Talks | 2021 Oncology Days
    Conference Dates: February 11-12, 2021
    Presentation Date: Thursday, February 11, 2021
    Presentation Time: 1:00 p.m. EST / 10:00 a.m. PST
  • 10th Annual SVB Leerink Global Healthcare Conference
    Conference Dates: February 22-26, 2021
    Presentation Date: Wednesday, February 24, 2021
    Presentation Time: 3:00 p.m. EST / 12:00 p.m. PST

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.



Xencor Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Xencor to Present at Upcoming Investor Conferences Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel